Risk Factors for Cardiovascular Events in Patients on Antidementia Medications.

IF 4.7 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2020-01-01 DOI:10.1177/1533317520922380

Meiqi He, James M Stevenson, Yuting Zhang, Inmaculada Hernandez

{"title":"Risk Factors for Cardiovascular Events in Patients on Antidementia Medications.","authors":"Meiqi He, James M Stevenson, Yuting Zhang, Inmaculada Hernandez","doi":"10.1177/1533317520922380","DOIUrl":null,"url":null,"abstract":"Objective: To identify characteristics associated with an increased risk of cardiovascular events in patients diagnosed with Alzheimer disease (AD) and treated with antidementia medications.Methods: Demographics, diagnoses, and medication usage of 30 433 Medicare patients were analyzed using 2006 to 2013 claims data and a combined model of screening, ranking and stepwise logistic regressions to evaluate factors associated with composite outcomes of 6 cardiovascular events.Results: Incidence rate of at least 1 cardiovascular event was 25.1%. Fifty-five factors were identified from the 10 381 candidate variables by the combined model with a c-statistic of 67% and an accuracy of 75%. Factors associated with increased risk of cardiovascular events include history of heart rhythm disorders, alteration of consciousness (odds ratio [OR]: 1.25; 95% confidence interval [CI]: 1.14-1.36), and usage of β-blockers (OR: 1.19; 95% CI: 1.13-1.27).Conclusions: Clinicians should consider the increased risk of cardiovascular events in patients with AD with heart rhythm disorders and on β-blockers.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":" ","pages":"1533317520922380"},"PeriodicalIF":4.7000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315406/pdf/nihms-1600948.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1533317520922380","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To identify characteristics associated with an increased risk of cardiovascular events in patients diagnosed with Alzheimer disease (AD) and treated with antidementia medications.

Methods: Demographics, diagnoses, and medication usage of 30 433 Medicare patients were analyzed using 2006 to 2013 claims data and a combined model of screening, ranking and stepwise logistic regressions to evaluate factors associated with composite outcomes of 6 cardiovascular events.

Results: Incidence rate of at least 1 cardiovascular event was 25.1%. Fifty-five factors were identified from the 10 381 candidate variables by the combined model with a c-statistic of 67% and an accuracy of 75%. Factors associated with increased risk of cardiovascular events include history of heart rhythm disorders, alteration of consciousness (odds ratio [OR]: 1.25; 95% confidence interval [CI]: 1.14-1.36), and usage of β-blockers (OR: 1.19; 95% CI: 1.13-1.27).

Conclusions: Clinicians should consider the increased risk of cardiovascular events in patients with AD with heart rhythm disorders and on β-blockers.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

服用抗痴呆药物的患者发生心血管事件的风险因素。

目的确定被诊断为阿尔茨海默病（AD）并接受抗痴呆药物治疗的患者中与心血管事件风险增加相关的特征：利用 2006 年至 2013 年的理赔数据分析了 30 433 名医疗保险患者的人口统计学特征、诊断和用药情况，并采用筛选、排序和逐步逻辑回归相结合的模型评估与 6 次心血管事件综合结果相关的因素：至少1例心血管事件的发生率为25.1%。综合模型从 10 381 个候选变量中识别出 55 个因素，c 统计量为 67%，准确率为 75%。与心血管事件风险增加相关的因素包括心律紊乱病史、意识改变（比值比 [OR]：1.25；95% 置信区间 [CI]：1.14-1.36）和使用β-受体阻滞剂（OR：1.19；95% CI：1.13-1.27）：临床医生应考虑到患有心律失常和服用β-受体阻滞剂的AD患者发生心血管事件的风险增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464

期刊介绍： ACS Applied Bio Materials is an interdisciplinary journal publishing original research covering all aspects of biomaterials and biointerfaces including and beyond the traditional biosensing, biomedical and therapeutic applications. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrates knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important bio applications. The journal is specifically interested in work that addresses the relationship between structure and function and assesses the stability and degradation of materials under relevant environmental and biological conditions.